PMOS and Your Heart: The Cardiometabolic Risk No One Told You About

When women are diagnosed with PMOS, the conversation typically focuses on periods, fertility, weight, and skin. These are the symptoms that bring patients to the doctor and the outcomes that matter most in the short term. But there is a longer-term risk that the old name “PCOS” systematically buried, and the PMOS rename is designed, in part, to force into clinical view.

PMOS is a cardiovascular risk condition. Not a minor one. A significant one that begins accumulating decades before events typically occur.

The Risk Nobody Talks About

A 2024 systematic review and meta-analysis published in the Journal of the American Heart Association confirmed what cardiologists had suspected for years: women with PMOS face significantly elevated risk for cardiovascular events including myocardial infarction, stroke, and coronary artery disease. This risk persists after adjusting for body weight, meaning it is not simply a consequence of obesity.

The problem is that cardiovascular disease typically presents in women 10 to 15 years later than in men, often after menopause. By the time a woman with PMOS has a cardiovascular event in her 50s or 60s, the metabolic damage has been accumulating since her 20s. If she was never diagnosed with PMOS, or if her PMOS was managed only as a reproductive condition, decades of cardiovascular risk went unmonitored and unmitigated.

Why PMOS Is a Cardiovascular Condition

The metabolic features that define PMOS are the same features that drive atherosclerosis and cardiovascular disease. This is not coincidence. It is the same underlying pathophysiology expressing itself in two organ systems.

Insulin resistance promotes dyslipidemia, endothelial dysfunction, and pro-thrombotic states. Chronic inflammation damages blood vessel walls and promotes plaque formation. Hyperandrogenism in women is associated with unfavorable lipid profiles and increased visceral adiposity. And the metabolic syndrome features that cluster with PMOS, including hypertension, elevated triglycerides, low HDL, and impaired glucose tolerance, are each independent cardiovascular risk factors.

The Numbers

Studies consistently show that women with PMOS have higher rates of several cardiovascular risk markers compared to age-matched controls.

Dyslipidemia is present in 70 percent of women with PMOS. Metabolic syndrome prevalence is 2 to 3 times higher than in age-matched women without the condition. Subclinical atherosclerosis, measured by carotid intima-media thickness, is increased even in young, lean women with PMOS. Coronary artery calcification scores are elevated in women with PMOS as early as their 30s and 40s.

Type 2 diabetes risk is 4 to 8 times higher in women with PMOS. Since diabetes itself doubles cardiovascular risk, this pathway alone represents a major threat.

Four Pathways to Cardiovascular Damage

Insulin Resistance and Dyslipidemia

Insulin resistance shifts the lipid profile toward atherogenic small dense LDL particles, elevated triglycerides, and reduced HDL. This pattern, sometimes called “atherogenic dyslipidemia,” is a stronger predictor of cardiovascular events than total cholesterol alone. It is present in the majority of PMOS patients.

Chronic Inflammation

Elevated CRP, IL-6, and TNF-alpha in PMOS directly damage the vascular endothelium. Inflammation destabilizes atherosclerotic plaques, making them more prone to rupture. This is the mechanism behind acute coronary events even in relatively young women.

Endothelial Dysfunction

The endothelium, the inner lining of blood vessels, regulates vascular tone and prevents clot formation. Studies show impaired endothelial function in young women with PMOS, measured by flow-mediated dilation. This early vascular damage is a precursor to clinical atherosclerosis.

Hyperandrogenism

While testosterone has protective cardiovascular effects in men, excess androgens in women appear to have the opposite effect. Elevated free testosterone in women is associated with increased visceral fat, impaired glucose metabolism, and unfavorable lipid profiles. The androgenic environment of PMOS contributes independently to cardiovascular risk.

What Screening You Should Be Getting

If you have PMOS, the following cardiovascular screening should be part of your regular care, not just your reproductive care:

Annual: Blood pressure, fasting lipid panel (total cholesterol, LDL, HDL, triglycerides), fasting glucose, and HbA1c.

At diagnosis and every 3 to 5 years: Fasting insulin and HOMA-IR to track insulin resistance trajectory. Oral glucose tolerance test (OGTT) if HbA1c is borderline.

Consider in your 30s to 40s: Coronary artery calcium (CAC) score if you have multiple metabolic risk factors. Carotid intima-media thickness (CIMT) if available. These can reveal subclinical atherosclerosis decades before symptoms appear.

Peptides and Cardiovascular Protection

Several peptide therapies relevant to PMOS have demonstrated cardiovascular benefits, making them doubly relevant for this population.

GLP-1 Receptor Agonists

Semaglutide has been shown to reduce major adverse cardiovascular events (MACE) in high-risk populations. The SELECT trial demonstrated a 20 percent reduction in MACE with semaglutide in overweight or obese adults with established cardiovascular disease. While this trial was not specific to PMOS, the metabolic profile of PMOS patients suggests they may derive similar cardiovascular protection.

Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing, with results expected to further clarify the cardioprotective potential of dual GIP/GLP-1 agonism.

MOTS-C

MOTS-C is a mitochondrial-derived peptide that activates AMPK, a master regulator of cellular energy metabolism. Preclinical data suggests MOTS-C improves insulin sensitivity, reduces inflammation, and may protect against atherosclerosis progression. It was nominated for the July 2026 FDA PCAC meeting for both obesity and osteoporosis indications.

NAD+ Precursors

NAD+ levels decline with age and are further depleted by the metabolic stress of insulin resistance. NAD+ supplementation or precursor therapy may support mitochondrial function, reduce oxidative stress, and improve endothelial health. While clinical evidence specifically in PMOS is limited, the mechanistic rationale is strong.

What to Do Now

Do not wait for symptoms. Cardiovascular disease in women is often asymptomatic until a major event. If you have PMOS, proactive screening and metabolic management are the most important long-term health decisions you can make.

Request the screening panel outlined above. If your current provider focuses only on reproductive aspects, ask for a referral to endocrinology or cardiology for comprehensive metabolic and cardiovascular assessment. The PMOS rename gives you clinical language to advocate for this care.